Core Viewpoint - The announcement details the public disclosure and verification of the incentive plan for restricted stock for the year 2025 by Xi'an Kangtuo Medical Technology Co., Ltd, ensuring compliance with relevant regulations and confirming the qualifications of the proposed incentive recipients [2][3][4]. Disclosure and Verification - The company held meetings on April 28, 2025, to approve the draft of the 2025 restricted stock incentive plan and related proposals, which were disclosed on the Shanghai Stock Exchange website [2]. - The public disclosure period for the proposed incentive recipients was from May 6 to May 15, 2025, during which no objections were raised [3]. - The supervisory board verified the qualifications of the proposed recipients against various legal and regulatory standards, confirming that they meet the necessary criteria [3][4]. Supervisory Board's Verification Opinion - The supervisory board concluded that all proposed incentive recipients meet the qualifications set forth by the Company Law, Securities Law, and other relevant regulations, confirming their eligibility for the incentive plan [4][5].

Core Points - The company has announced the public disclosure of the list of initial grant recipients for its 2025 Restricted Stock Incentive Plan [1][2] - The public disclosure period for the incentive plan is from April 29, 2025, to May 8, 2025, lasting a total of 10 days [2] - The supervisory board has confirmed that no objections were raised during the public disclosure period [2] - The supervisory board has verified the qualifications of the proposed recipients against relevant laws and regulations [3][4] Summary by Sections Public Disclosure and Verification - The company disclosed the 2025 Restricted Stock Incentive Plan and the list of initial grant recipients on the Shanghai Stock Exchange website on April 29, 2025 [1] - Employees were allowed to submit suggestions to the supervisory board during the public disclosure period, which lasted 10 days [2] - No objections were received by the supervisory board regarding the proposed recipients [2] Supervisory Board's Verification Opinion - The supervisory board has verified that all proposed recipients meet the qualifications set forth in the relevant laws, regulations, and the company's articles of association [3] - The initial grant recipients do not include independent directors, supervisors, shareholders holding more than 5% of the company's shares, or the actual controller and their immediate family members [3][4] - The supervisory board concludes that the qualifications of the proposed recipients are legal and valid under the 2025 Restricted Stock Incentive Plan [4]

Core Viewpoint - The legal opinion issued by Zhejiang Liuhe Law Firm confirms that Hangzhou Yongchuang Intelligent Equipment Co., Ltd. has met the necessary conditions for the release of restrictions on its 2021 restricted stock incentive plan, in compliance with relevant laws and regulations [2][12]. Group 1: Legal Framework and Approval Process - The law firm was commissioned to provide legal advice based on the Company Law, Securities Law, and the Management Measures for Incentive Plans [2]. - The company held multiple board and supervisory meetings to approve the incentive plan and its related matters, including the review of the incentive object list and the authorization for the board to handle related affairs [3][4][5][6][7][8]. - The independent directors provided their opinions supporting the implementation of the incentive plan [3][4][5]. Group 2: Conditions for Release of Restrictions - The release of restrictions is contingent upon meeting specific performance targets outlined in the incentive plan, which includes revenue and net profit growth rates compared to 2020 [13][14][15]. - The company reported a revenue of 3.146 billion yuan for 2023, meeting the performance target for the third release period of the incentive plan [15]. - The performance evaluation results for the 125 incentive objects were all rated as good or above, allowing for the full release of restrictions [15]. Group 3: Conclusion and Compliance - The law firm concluded that all necessary approvals and authorizations for the release of restrictions have been obtained, and the conditions set forth in the incentive plan have been satisfied [12][15]. - The release of restrictions aligns with the provisions of the Company Law, Securities Law, and the Management Measures for Incentive Plans [12].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为979,650股。 ? 本次股票上市流通日期为2025 年 5 月 20 日。 证券代码：603551 证券简称：奥普科技 公告编号：2025-031 奥普智能科技股份有限公司 关于 2023 年限制性股票激励计划首次授予部分 第二个解锁期解锁上市的公告 奥普智能科技股份有限公司（以下简称"公司"、"奥普科技"）于 2025 年 4 月 了《关于 2023 年限制性股票激励计划首次授予部分第二个解锁期解锁条件成就 的议案》，同意对符合第二个解锁期解锁条件的 979,650 股限制性股票办理解除 限售，本次解除限售事项已经公司 2023 年第一次临时股东大会授权，无需再提 交股东大会审议。现将相关事项公告如下： 一、 股权激励计划限制性股票批准及实施情况 公司 2023 年限制性股票激励计划实施考核管理办法>的议案》、《关于核查< 2023 年限制性股票激励计划激励对象名单 ...

Core Points - The company Matrix Holdings has publicly disclosed the list of incentive objects for the 2025 Restricted Stock Incentive Plan, ensuring the information is true, accurate, and complete [1] - The incentive plan was approved in the 11th meeting of the board and the supervisory board, following relevant regulations and guidelines [1][2] - The public disclosure of the incentive plan and the list of incentive objects occurred from April 10 to April 23, 2025, with no objections raised during this period [2] Disclosure Details - The public disclosure included the names and positions of the incentive objects [2] - The disclosure was made through the company's collaborative office system [2] - The remuneration and assessment committee verified the list of proposed incentive objects and found no objections or feedback during the public notice period [2] Verification Opinions - The remuneration and assessment committee confirmed that all proposed incentive objects meet the qualifications set forth in relevant laws and regulations [3] - The committee ensured that none of the proposed incentive objects fell under the disqualifications outlined in the management regulations and listing rules [2][3] - The incentive plan excludes independent directors and shareholders holding more than 5% of the company's shares, ensuring compliance with legal requirements [3]

证券代码：688513 证券简称：苑东生物 公告编号：2025-026 公司于 2025 年 4 月 29 日至 2025 年 5 月 8 日在公司内部 OA 对本次激励计 划预留授予激励对象的姓名和职务进行了公示，公示时间共 10 天，公司员工可 在公示期间以书面方式或邮件方式反映意见。 截至公示期满，公司监事会未收到任何员工对本次激励计划预留授予激励对 象名单提出的疑义或异议。 特此公告。 成都苑东生物制药股份有限公司 预留授予激励对象名单的公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第四届董事会第三次会议和第四届监事会第三次会议审议通过了《关于向 《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司股权激励 管理办法》等相关法律法规及《成都苑东生物制药股份有限公司章程》的有关规 定，公司对 2024 年限制性股票激励计划（以下简称"本次激励计划"）预留授予 激励对象的名单在公司内部进行了公示，相关公示情 ...

| 证券代码：600713 | 证券简称：南京医药 | | --- | --- | | 债券代码：110098 | 债券简称：南药转债 | | 上海荣正企业咨询服务（集团）股份有限公司 | | | | 关于 | | 南京医药股份有限公司 | | | 首次授予及调整相关事项 | | | | 之 | | 独立财务顾问报告 | | | | 目 录 | | 一、释义 | | | 以下词语如无特殊说明，在本文中具有如下含义： | | | 南京医药、本公 | | | 司、公司、上市公 | 指 南京医药股份有限公司 | | 司 | | | 股权激励计划、本 | | | 指 | 南京医药股份有限公司 2025 年限制性股票激励计划 | | 激励计划 | | | | 公司根据本激励计划规定的条件和价格，授予激励对象一 | | | 定数量的公司股票，该等股票设置一定期限的限售期，在 | | 限制性股票 指 | | | | 达到本激励计划规定的解除限售条件后，方可解除限售流 | | 通 | | | | 按照本激励计划规定，获得限制性股票的公司董事、高级 | | 激励对象 指 | | | | 管理人员、公司及控股子公司核心管理/骨干 ...

证券代码：600713 证券简称：南京医药 编号：ls2025-062 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于调整 2025 年限制性股票激励计划相关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、 《南京医药 股份有限公司 2025 年限制性股票激励计划（草案）》（以下简称"《激励计划》"） 的相关规定以及公司 2025 年第一次临时股东大会决议的授权，南京医药股份有限 公司（以下简称"公司"）于 2025 年 5 月 9 日召开第九届董事会第十次会议和第九 届监事会第十次会议，审议通过了《关于调整 2025 年限制性股票激励计划相关事 项的议案》，现将有关调整事项公告如下： 一、公司 2025 年限制性股票激励计划（以下简称"本次激励计划"）已履行 的决策程序和信息披露情况 《激励计划》及其摘要、《南京医药股份有限公司 2025 年限制性股票激励计划考 核管理办法》 《南京医药股份有限公司 2025 （以下简称"《激 ...

1、列入本激励计划首次授予激励对象名单的人员具备《中华人民共和国公司法》（以下简称"《公司 法》"）、《南京伟思医疗科技股份有限公司章程》等法律、法规和规范性文件规定的任职资格。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 2025年4月24日，南京伟思医疗科技股份有限公司（以下简称"公司"）第四届董事会第三次会议、第四 届监事会第三次会议审议通过了《关于〈公司2025年限制性股票激励计划（草案）〉及其摘要的议案》 等相关议案。根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）的相关规定，公司对 2025年限制性股票激励计划首次授予激励对象名单在公司内部进行了公示。公司监事会结合公示情况对 拟激励对象进行了核查，相关公示情况及核查情况如下： 一、公示情况及核查方式 1、公司对激励对象的公示情况 公司于2025年4月25日在上海证券交易所网站（www.sse.com.cn）上披露了《公司2025年限制性股票激 励计划（草案）》（以下简称"本激励计划"）及其摘要、《公司2025年限制性股票激励计划实施考核管 理办 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688516 证券简称：奥特维 公告编号：2025-044 转债代码：118042 转债简称：奥维转债 无锡奥特维科技股份有限公司 第四届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内 容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 无锡奥特维科技股份有限公司（以下简称"公司"）第四届监事会第十五次会议于2025年4月30日召开。 本次会议由监事会主席陈霞女士主持，应到监事3名，实到监事3名，符合《中华人民共和国公司法》 （以下简称"《公司法》"）和《公司章程》的规定。 二、监事会会议审议情况 经与会监事认真审议并表决，一致通过了如下事项： （一）审议通过《关于作废部分已授予尚未归属的限制性股票的议案》 经审核，监事会认为： 公司本次作废部分已授予尚未归属的限制性股票符合《公司法》《中华人民共和国证券法》《上市公司 股权激励管理办法》（以下简称"《管理办法》"）《上海证券交易所科创板股票上市规则》（以下简 称"《上市规则》"）等法律、法规、规范性文件及公司《 ...